COPD Trial, Recruiting NCT06772454 Sponsor: Guangzhou Institute of Respiratory Disease Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT06772454
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been confirmed through tissue or cell testing to have a specific type of advanced lung cancer called squamous non-small cell lung cancer, at stage IIIB or IV
  • People who have been diagnosed with stable moderate to severe chronic obstructive pulmonary disease (COPD) that is currently not in a flare-up, with a specific level of a blood cell type called eosinophils falling between 100 and 300 per microlitre
  • People whose lung cancer genetic testing has shown no changes in a specific set of genes (EGFR, ALK, BRAF, ROS1, KRAS, HER2, MET, RET, or NTRK)
  • People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale (ECOG PS), meaning they are able to carry out daily activities at least to some degree
  • People whose doctors have assessed them as suitable for a treatment combination involving a drug called suglizumab, two chemotherapy medicines (paclitaxel albumin-bound and carboplatin), and COPD inhalers (long-acting bronchodilators or inhaled corticosteroids)
  • People for whom medical records of their treatments are available
  • People who have previously used bronchodilator or inhaled corticosteroid inhalers, provided those inhalers have been stopped for at least 15 days before joining
  • People who agree to take part voluntarily and sign a consent form

Who may not be able to join:

  • People who currently have another active cancer in addition to squamous non-small cell lung cancer
  • People who have already received systemic treatment for advanced or metastatic non-small cell lung cancer
  • People who have a condition requiring long-term use of steroid medications taken by mouth or through a drip, such as autoimmune diseases, asthma, kidney inflammation, type 1 diabetes, or overactive thyroid
  • People who have taken steroid medications by mouth or through a drip for any reason in the month before screening
  • People whose doctors have assessed them as having serious liver or kidney problems
  • People who are experiencing acute breathing failure, or who need ongoing support from a breathing machine, or who have had two or more moderate to severe COPD flare-ups in the past year
  • People who are pregnant, breastfeeding, or planning to become pregnant
  • People who are currently enrolled in or planning to join another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13560351186

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Guangzhou Institute of Respiratory Disease
Registry
ClinicalTrials.gov
Start date
1 January 2023
Est. completion
30 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PSF、Time and severity of the first acute exacerbation of severe COPD (AECOPD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov